BiologicsMD

BiologicsMD is a private preclinical therapeutics company developing highly targeted parathyroid hormone receptor-mediated treatments for hair loss, bone disorders, and oncology-related bone disease. Its core approach uses patent-protected recombinant fusion proteins that combine an active domain with a proprietary collagen-binding domain to localize therapy to skin or bone and extend activity with infrequent dosing. The lead alopecia program, BMD-1141, is being developed for alopecia areata and has shown preclinical activity in multiple hair-loss models. The company is also advancing bone-focused programs including BMD-1111 for osteoporosis, BMD-1231 for spinal fusion, and earlier oncology-supportive programs for prevention and treatment of bone metastases. BiologicsMD positions its technology as a targeted biologic platform intended to improve efficacy while limiting off-target exposure.